Coriell Life Sciences

First-of-its-Kind Personalized 'COVID-19 Risk Score' Launches to Enable Safer Re-opening and Return to Work Plans

Coriell Life Sciences’ advanced data analytics examine individuals’ health history to identify those who are more likely to have severe or fatal outcomes if infected with novel coronavirus.
1-Jun-2020 9:00 AM EDT, by Coriell Life Sciences

Newswise — As more businesses and employees prepare to return to work around the country, Coriell Life Sciences (CLS) is rolling out a new tool in the fight against COVID-19: personalized COVID-19 Risk Scores.  Using proprietary, advanced data analytics, CLS analyzes information from medical records to identify the number of unique risk factors linked to poor COVID-19 outcomes an individual has.  Factors include thousands of potential risk elevators, from cardiovascular disease, diabetes and hypertension to allergies, anemia, and more.  The higher the number of risk factors, the higher the likelihood of experiencing severe or fatal symptoms if infected with the virus.

“This type of intelligence has the power to play a pivotal role in protecting the most vulnerable among us,” says Jeffrey A. Shaman, PhD, Chief Science Officer at Coriell Life Sciences.  “It’s clear people who suffer from chronic medical conditions are far more likely to fare poorly if they have COVID-19, but it’s hardly that simple.  Other factors, such as blood type and medications used, are also showing evidence they may be related to negative outcomes.  By analyzing individuals’ health history against thousands of medical codes that are aligned to risk factors for poor COVID-19 outcomes, we can determine who has the greatest risk of requiring acute care and empower them to be more vigilant in protecting their health.”

Individuals are eligible for COVID-19 risk scoring through participating employers.   

“Beyond empowering individuals to better protect their health, this information can also be used to help business leaders strategically tackle the high-stakes complexities surrounding when and how to get their teams back to work safely,” notes Coriell Life Sciences’ President & CEO Scott Megill.  “Both are critical elements in lessening the impact of this pandemic on public health and our country’s economic health.  The bottom line is we must make better use of the information that’s available today while the global scientific community remains keenly focused on scaling diagnostics and developing effective therapeutics and a viable vaccine.”

COVID-19 risk scoring is part of CLS’ new Return to Work Program.  This program provides an intelligence-driven solution designed to help organizations safely resume operations.  In addition to analyzing employee and facility data to illuminate risks and barriers to re-opening, the program offers businesses turnkey infrastructure for managing large-scale COVID-19 testing of employees in partnership with a network of laboratories across the country.

A leader in genetic science, CLS also enables organizations to help employees advocate for their health by offering personalized COVID-19 Genetic Drug Safety Reports.  Based on preemptive DNA testing, this report reveals how an individual would likely respond to approximately 45 drugs that could be used during COVID-19 treatment and have known genetic implications.  This information can be provided to a physician or pharmacist to inform an effective treatment plan.

“The reality is that some drugs just don’t work for some people,” notes Dr. Shaman.  “Some aren’t safe for one person but are completely fine for another.  Differences in our DNA are responsible for some of this variation.  Precision medicine enables us to determine which drugs will be both safe and effective for patients with COVID-19 – as well as many other conditions.” 

To learn more, visit coriell.com.

 

About Coriell Life Sciences

Coriell Life Sciences (CLS), a leader in genetic science, uses innovation in precision medicine to reduce healthcare costs and empower a healthier world.  With scientific expertise that spans six decades, CLS bridges the gap between genetic knowledge and clinical application and offers the most comprehensive medication risk management program on the market.  Visit coriell.com, email info@coriell.com or follow @CoriellLife.

# # #




Filters close

Showing results

110 of 2552
14-Jul-2020 8:55 AM EDT
Rapid genome sequencing and screening help hospital manage COVID-19 outbreaks
University of Cambridge

Cambridge researchers have shown how rapid genome sequencing of virus samples and enhanced testing of hospital staff can help to identify clusters of healthcare-associated COVID-19 infections.

Newswise: 236709_web.jpg
Released: 14-Jul-2020 3:05 PM EDT
When a pandemic strikes, we still expect an ambulance
Edith Cowan University

Research published today has found that Australians strongly believe paramedics deserve a work environment free from the threat of physical harm, but when it comes to the risk of infectious disease, it's complicated.

Newswise: Story Tips From Johns Hopkins Experts on COVID-19
Released: 14-Jul-2020 12:40 PM EDT
Story Tips From Johns Hopkins Experts on COVID-19
Johns Hopkins Medicine

Sharon Tapp, who worked as a nurse case manager at Veterans Affairs Medical Center in Washington, D.C., started experiencing sudden body weakness, chest pain, a high temperature and headache on March 18. Concerned, she went to her local urgent care center to find out what was wrong. They told her that these symptoms were flu-like, tested her for the coronavirus and told her to quarantine for 14 days. After five days and no difference in the presentation of her symptoms, the urgent care team contacted Sharon, letting her know that she tested positive for coronavirus and recommending that she go to the emergency department. Sharon’s family took her to Johns Hopkins Medicine’s Suburban Hospital. Because her condition worsened while at Suburban, she was transferred to The Johns Hopkins Hospital in Baltimore within 10 days of being admitted to Suburban Hospital.

Released: 14-Jul-2020 12:05 PM EDT
National Glaucoma Research Foundation Survey Reveals Glaucoma Patients’ Experiences and Concerns During COVID-19 Pandemic
Glaucoma Research Foundation

National survey finds appointment delays and cancellations were the greatest cause of concern; waiting for in-person appointments is greatly preferred over telemedicine.

Newswise: Palliative Nursing’s Role During COVID-19 and Beyond
Released: 14-Jul-2020 11:35 AM EDT
Palliative Nursing’s Role During COVID-19 and Beyond
University of Pennsylvania School of Nursing

As a rapid influx of patients overwhelmed health systems during the coronavirus pandemic, palliative nurses played dual roles supporting patients, patient families, and colleagues. Two researchers at the University of Pennsylvania School of Nursing (Penn Nursing) are among those detailing the important role palliative care has in responding during the COVID-19 pandemic and in future public health crises.

Newswise: 237436_web.jpg
Released: 14-Jul-2020 11:20 AM EDT
New study shows SARS-CoV-2 viral load peaks in the early stages of disease
Elsevier

In a retrospective study, investigators from New York University Langone Health found that the quantity of SARS-CoV-2 (viral load) collected from patients in the emergency department is significantly higher in patients with fewer or milder symptoms who did not require hospitalization--the opposite of what might be expected.

Newswise: Hackensack Meridian CDI has Struck a COVID-19 Research Collaboration with Merck
Released: 14-Jul-2020 10:00 AM EDT
Hackensack Meridian CDI has Struck a COVID-19 Research Collaboration with Merck
Hackensack Meridian Health

The CDI will work with Merck to identify candidate treatments for the still-spreading pandemic.

Released: 14-Jul-2020 9:00 AM EDT
COVID-19 pandemic could be learning opportunity for middle-grade students
Binghamton University, State University of New York

Educators could use the COVID-19 outbreak to help middle-schoolers better understand the world, according to new research from faculty at Binghamton University, State University of New York.


Showing results

110 of 2552

close
1.90264